Eurofins Increases Testing Capacity to Support Food Industry in Responding to Horsemeat Scandal and Offers Tamper-Proof

  Eurofins Increases Testing Capacity to Support Food Industry in Responding
  to Horsemeat Scandal and Offers Tamper-Proof Analytical Traceability™

Business Wire

LUXEMBOURG -- February 13, 2013

Regulatory News :

Eurofins Scientific (Paris:ERF) (EUFI.PA), the global leader in food and feed
testing, announces that it has recently increased its testing capacity to
detect horse meat in meat products by reallocating some of the equipment from
its other lines of molecular testing. Eurofins currently has the largest
capacity for authenticity and DNA analysis of any independent food testing
service provider to address the ongoing horsemeat scandal in Europe. In
addition, the Group is able to easily further ramp-up local capacities, given
the scalable model of its large laboratories.

The Group’s Competence Centre for DNA Analysis in Ebersberg, Germany was the
first independent laboratory that confirmed the contamination of beef with
horse meat in Ireland^1 having been commissioned by the Food Safety Authority
of Ireland (FSAI)^2 to conduct independent testing on meat samples at the end
of December 2012. The Ebersberg laboratory is presently already rolling-out
its competencies in DNA analyses to the rest of Eurofins’ large laboratories
in Europe to assist the food industry across the entire supply chain to
respond swiftly and appropriately to the ongoing scandal.

Eurofins has been pioneering DNA-based analytical technologies for meat
testing to supply industrial customers with innovative protocols to improve
the safety and authenticity of their food products for over 10 years. This
expertise was demonstrated during the outbreak of Bovine Spongiform
Encephalopathy (BSE) in Europe in 2000^3, when Eurofins was the first
laboratory to release a DNA-test enabling the tracing of individual cow meat
across the supply chain. In 2005, Eurofins also developed a test to determine
the authenticity of Aberdeen Angus Beef^4. These examples illustrate Eurofins’
unparalleled analytical and technological capability to support customers’
efforts in ensuring the authenticity, accuracy and safety of their products.
These capabilities can go well beyond the identification of one animal
species, they can also be used to ensure individual breeds or even enable the
exact traceability of individual animals throughout the food chain. In
contrast to paper traceability, Analytical Traceability™ based on DNA and
other markers cannot be forged.

Following intense investments in recent years in the latest technology and to
ensure that it has the highest capacity, Eurofins is currently the largest
private independent laboratory in the world for DNA sample testing, with more
than 10,000 samples being tested every day in its laboratories. Since the
start of the horse meat crisis, Eurofins has already tested thousands of
processed meat samples and continues to scale up its capacity by allocating
more of its DNA-testing resources to this specific type of samples. The Group
has the capacity to efficiently handle the marked increase in daily volume of
samples, whilst maintaining the accuracy and reliability of its analyses.
State-of-the-art Real-Time PCR and sequencing technology allow Eurofins to
deliver validated results within 48 hours. Furthermore, for more urgent
analyses, Eurofins also has the capability to provide indicative results
within 24 hours. Testing can also be done on the same sample for a range of
other species which could be present in meat or for residues of pharmaceutical
or other chemicals or heavy metals.

Eurofins is also developing new protocols based on the latest innovation in
sequencing technologies (Next Generation sequencing) which should lead to a
significant increase in its DNA-testing capacity and significantly reduce the
cost per analysis allowing a more systematic authenticity testing for each
batch of meat, as well as of many other food products, economically viable.
This innovative technology will introduce a new paradigm for untargeted
testing to detect all present contaminants, instead of the current practice of
testing for a pre-determined list of contaminants.

^1 Irish Times 17 January, 2013 “DNA profiling leaves no room for beefs”.
^3 Eurofins Press Release dated 22 November 2000
^4 Eurofins Press Release dated 22 June2005

For more information, please visit www.eurofins.comNotes for the editor:

Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food and pharmaceutical products
testing. It is also number one in the world in the field of environmental
laboratory services and one of the global market leaders in agroscience,
genomics, discovery pharmacology and central laboratory services.

With over 13,000 staff in more than 170 laboratories across 34 countries,
Eurofins offers a portfolio of over 100,000 reliable analytical methods for
evaluating the safety, identity, composition, authenticity, origin and purity
of biological substances and products. The Group provides its customers with
high-quality services, accurate results in time and expert advice by its
highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding
both its technology portfolio and its geographic reach. Through R&D and
acquisitions, the Group draws on the latest developments in the field of
biotechnology and analytical chemistry to offer its clients unique analytical
solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in
its industry, Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the expanding demands
of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock
Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that
involve risks and uncertainties. The forward-looking statements and estimates
contained herein represent the judgement of Eurofins Scientific’ management as
of the date of this release. These forward-looking statements are not
guarantees for future performance, and the forward-looking events discussed in
this release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and estimates.
All statements and estimates are made based on the data available to the
Company as of the date of publication, but no guarantee can be made as to
their validity.


Eurofins Investor Relations
Phone: +32-2-766 1620
Press spacebar to pause and continue. Press esc to stop.